Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024


AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.


These press releases may also interest you

at 06:00
Anti-Migrating Agent Market worth $224 million by 2029 - Exclusive Report by MarketsandMarketstm
The report "Anti-Migrating Agent Market by Type (Non-ionic, Anionic, Cationic, Amphoteric), Grades (Technical, Food, Pharmaceutical), Application, Chemistry (Organic, Inorganic), End-Use Industry (Textile, Plastics, Paper), and Region - Global...

at 05:42
Gupshup and Meta along with Sudan Medical Specialization Board and Shabaka launch Telemedicine Chatbot for Sudanese Refugees
Gupshup, the world's leading Conversation Cloud, in collaboration with Meta, the Sudan Medical Specialization Board and non-profit Shabaka today announced the launch of a telemedicine chatbot providing healthcare access for Sudanese refugees in...

at 05:23
ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...

at 05:00
Specialty Enzymes Market worth $9.2 billion by 2029 - Exclusive Report by MarketsandMarketstm
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...

at 05:00
Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...

at 04:37
Cytotoxic Drugs and HPAPI Manufacturing Market worth USD 27.1 Billion to 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing  Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...

More news about Health...


News published on and distributed by: